Marisa Wexler, MS,  senior science writer—

Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…

The Pulmonary Hypertension Association (PHA) is fundraising and advocating with a campaign called “Let Your Light Shine” this November for this year’s pulmonary hypertension (PH) awareness month. “The efforts of PHA and the PH community are making a tremendous impact on the lives of those affected by PH,”…

Researchers at Monash University in Australia will use newly granted funding to advance their work on a project that aims to create a novel disease-modifying treatment for pulmonary arterial hypertension (PAH). That funding came from Biocurate, a venture led by the University of Melbourne and Monash that aims…

An upcoming clinical trial will test whether empagliflozin, a drug widely approved to treat diabetes and heart failure, might be able to improve heart health in people with pulmonary arterial hypertension (PAH). The trial will be led by scientists at Cleveland Clinic, with study sites planned at two…

For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with macitentan and tadalafil is similarly effective, according to a new analysis by researchers in the U.S. and Europe. “Initial combination therapy with macitentan plus tadalafil is efficacious in patients with…

The U.S. Food and Drug Administration has given Tectonic Therapeutic the go-ahead to start a Phase 2 clinical trial of TX45, the company’s experimental treatment for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). “We remain enthusiastic about the potential of TX45 to address the…

A committee of the European Medicines Agency (EMA) has recommended that Yuvanci, a tablet containing macitentan and tadalafil, be approved for pulmonary arterial hypertension (PAH). The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) specifically recommends Yuvanci be approved for PAH in individuals with…

Tempus AI and United Therapeutics are teaming up for a study to advance the use of artificial intelligence (AI) for detecting people at risk of having undiagnosed pulmonary hypertension. “We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into…

The amount of normal-looking lung tissue visible on CT scans of the chest can help to predict survival outcomes and response to treatment in people with pulmonary hypertension (PH), a study found. The study, “Significance of normal lung volume on quantitative computed tomography analysis in Group…

Chronic alcohol consumption damages the heart and blood vessels in ways that seem to set the stage for pulmonary arterial hypertension (PAH), according to a study in male rats. These findings “yield new insight into the adverse effect of ethanol on cardiopulmonary [heart and lung] health, providing a foundation…

A noninvasive intervention that makes use of ultrasound to target the splenic nerve — a nerve in the spleen, an organ in which immune cells develop — was found to reduce inflammation and the severity of pulmonary arterial hypertension (PAH) in rat models of the disease, according to a…

The American Kidney Fund (AKF) has awarded an early-career fellowship that will support new research aiming to understand how pulmonary hypertension (PH) develops in people with chronic kidney disease. The project will be led by Marcelle Tuttle, MD, a first-year fellow at the Tufts Medical Center division of…